Sax Wealth Advisors LLC Acquires 4,692 Shares of AbbVie Inc. $ABBV

Sax Wealth Advisors LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 40.5% in the third quarter, Holdings Channel reports. The institutional investor owned 16,271 shares of the company’s stock after buying an additional 4,692 shares during the quarter. Sax Wealth Advisors LLC’s holdings in AbbVie were worth $4,256,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of ABBV. State Street Corp raised its stake in AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after purchasing an additional 106,091 shares during the last quarter. Legal & General Group Plc bought a new position in shares of AbbVie during the 2nd quarter worth about $2,905,952,000. Deutsche Bank AG increased its holdings in shares of AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock worth $2,710,905,000 after purchasing an additional 1,241,587 shares during the period. Finally, Amundi raised its position in shares of AbbVie by 2.4% during the first quarter. Amundi now owns 10,698,095 shares of the company’s stock valued at $2,326,728,000 after buying an additional 247,689 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ABBV shares. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 target price on shares of AbbVie in a research note on Tuesday. Bank of America restated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. JPMorgan Chase & Co. boosted their price target on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Weiss Ratings upgraded AbbVie from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 5th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, AbbVie has an average rating of “Moderate Buy” and a consensus price target of $277.18.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating and set a $280 price target, indicating continued confidence in AbbVie’s outlook, although the target implies only modest near-term upside. TickerReport article
• Positive Sentiment: Skyrizi and Rinvoq are expected to be the primary drivers of third-quarter revenue growth, helping offset the continued decline of Humira. Long-term data presented at ACG 2026 also support the durability of these products. Yahoo Finance article
• Positive Sentiment: Investors remain focused on AbbVie’s pipeline expansion, including a recently completed acquisition and a new FDA approval that could create another billion-dollar growth opportunity. 247WallSt article
• Neutral Sentiment: AbbVie was highlighted in broader discussions of pharmaceutical merger activity, as large drugmakers pursue acquisitions to address upcoming patent cliffs. This supports sector interest but does not provide a company-specific catalyst by itself. ETF Trends article
• Negative Sentiment: Humira’s ongoing erosion and increasing competition in immunology remain key risks. In addition, AbbVie’s elevated valuation and the limited upside to RBC’s target may encourage investors to lock in gains after the stock’s recent rally. Motley Fool article

AbbVie Trading Down 1.6%

NYSE ABBV traded down $4.53 on Tuesday, reaching $276.59. The company’s stock had a trading volume of 1,887,364 shares, compared to its average volume of 6,390,898. The firm has a market cap of $488.67 billion, a PE ratio of 78.17, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. The business has a 50-day moving average price of $259.79 and a 200 day moving average price of $237.39. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $283.43.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Analysts anticipate that AbbVie Inc. will post 13.94 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.